









Markets
/
Stocks
/
nasdaq-xfor
/

X4 Pharmaceuticals Inc

XFOR

3.170USD

-0.070-2.16%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

25.23MMarket Cap

LossP/E TTM



X4 Pharmaceuticals Inc

3.170

-0.070-2.16%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

95 / 175

Overall Ranking

286 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.700

Target Price

+168.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.56M.

Overvalued

The company’s latest PE is -0.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.50M shares, decreasing 33.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 231.89K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 13.21.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.22, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.97M, representing a year-over-year increase of 250.44%, while its net profit experienced a year-over-year increase of 128.34%.

Score

Industry at a Glance

Previous score

6.22

Change



Financials

5.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.89

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.81

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.59

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.35, which is 688.81% below the recent high of -2.73 and -13374.09% above the recent low of -46.59.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.40, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for X4 Pharmaceuticals Inc is 9.00, with a high of 14.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.700

Target Price

+168.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

X4 Pharmaceuticals Inc

XFOR

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.66, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 4.48 and the support level at 2.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.66

Change

-0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.193

Neutral

RSI(14)

50.616

Neutral

STOCH(KDJ)(9,3,3)

42.186

Buy

ATR(14)

0.392

Low Volatility

CCI(14)

-50.849

Neutral

Williams %R

68.132

Sell

TRIX(12,20)

0.625

Sell

StochRSI(14)

70.282

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.130

Buy

MA10

3.227

Sell

MA20

3.529

Sell

MA50

2.574

Buy

MA100

2.778

Buy

MA200

8.010

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 59.08%, representing a quarter-over-quarter increase of 1.55%. The largest institutional shareholder is The Vanguard, holding a total of 231.89K shares, representing 2.03% of shares outstanding, with 57.73% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

499.56K

Bain Capital Life Sciences Investors, LLC

563.86K

Kingdon Capital Management, L.L.C.

233.33K

+41.79%

The Vanguard Group, Inc.

Star Investors

268.92K

-1.63%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.94, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.